Cargando…
Multiple Sclerosis: Immunopathology and Treatment Update
The treatment of multiple sclerosis (MS) has changed over the last 20 years. All immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a medical challenge in MS to develop a treatment for progressive forms. The most common injectable disease-modifying therapies in RRMS in...
Autores principales: | Dargahi, Narges, Katsara, Maria, Tselios, Theodore, Androutsou, Maria-Eleni, de Courten, Maximilian, Matsoukas, John, Apostolopoulos, Vasso |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532591/ https://www.ncbi.nlm.nih.gov/pubmed/28686222 http://dx.doi.org/10.3390/brainsci7070078 |
Ejemplares similares
-
Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis
por: Day, Stephanie, et al.
Publicado: (2015) -
Streptococcusthermophilus ST285 Alters Pro-Inflammatory to Anti-Inflammatory Cytokine Secretion against Multiple Sclerosis Peptide in Mice
por: Dargahi, Narges, et al.
Publicado: (2020) -
Advances in Multiple Sclerosis Research–Series I
por: Apostolopoulos, Vasso, et al.
Publicado: (2020) -
The Long Road of Immunotherapeutics against Multiple Sclerosis †
por: Apostolopoulos, Vasso, et al.
Publicado: (2020) -
Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
por: Florou, Despoina, et al.
Publicado: (2020)